ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RACC icon
76
Research Alliance Corp III
RACC
$92.4M
$6.96M 0.32%
+650,000
New +$6.77M
2026 Q2
0 quarters
IFRX icon
77
InflaRx
IFRX
$218M
$6.72M 0.31%
3,000,000
+2,841,729
+1,795% +$5.34M
2026 Q1
1 quarter
RLAY icon
78
Relay Therapeutics
RLAY
$3.74B
$6.7M 0.31%
+358,333
New +$5.2M
2026 Q2
0 quarters
JANX icon
79
Janux Therapeutics
JANX
$1.05B
$6.46M 0.3%
420,881
+122,335
+41% +$1.77M
2024 Q1
9 quarters
PLRX icon
80
Pliant Therapeutics
PLRX
$54.7M
$6.28M 0.29%
5,509,724
+2,924,598
+113% +$3.56M
2025 Q4
2 quarters
WHWK icon
81
Whitehawk Therapeutics
WHWK
$169M
$6.14M 0.28%
1,341,394
+1,212,891
+944% +$5.05M
2025 Q4
2 quarters
KRYS icon
82
Krystal Biotech
KRYS
$9.79B
$6.1M 0.28%
16,420
-3,594
-18% -$1.07M
2025 Q3
3 quarters
ABUS icon
83
Arbutus Biopharma
ABUS
$830M
$6.09M 0.28%
1,268,147
-1,865,028
-60% -$8.19M
2023 Q4
10 quarters
PFE icon
84
Pfizer
PFE
$166B
$6.08M 0.28%
252,400
+175,000
+226% +$4.58M
2023 Q4
10 quarters
BHF icon
85
Brighthouse Financial
BHF
$2.75B
$6.05M 0.28%
95,523
– –
2025 Q3
3 quarters
ABVX icon
86
CALL
Abivax
ABVX
$7.68B
$5.92M 0.27%
44,400
+400
+0.9% +$45.3K
2026 Q1
1 quarter
EWTX icon
87
Edgewise Therapeutics
EWTX
$4.02B
$5.82M 0.27%
143,199
+52,600
+58% +$1.81M
2025 Q1
5 quarters
ALEC icon
88
Alector
ALEC
$210M
$5.8M 0.27%
2,883,583
+1,833,583
+175% +$3.93M
2025 Q4
2 quarters
FULC icon
89
Fulcrum Therapeutics
FULC
$280M
$5.73M 0.26%
1,565,029
+1,434,469
+1,099% +$8.73M
2023 Q4
10 quarters
ARWR icon
90
Arrowhead Research
ARWR
$8.25B
$5.69M 0.26%
69,800
-500
-0.7% -$36.9K
2023 Q4
10 quarters
ABOS icon
91
Acumen Pharmaceuticals
ABOS
$127M
$5.64M 0.26%
2,111,334
-45,000
-2% -$111K
2024 Q4
6 quarters
OACCU icon
92
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$5.6M 0.26%
516,482
– –
2024 Q4
6 quarters
GMED icon
93
Globus Medical
GMED
$10.2B
$5.54M 0.25%
70,100
+50,000
+249% +$4.25M
2025 Q4
2 quarters
GLUE icon
94
Monte Rosa Therapeutics
GLUE
$839M
$5.25M 0.24%
216,752
+1,000
+0.5% +$18.9K
2025 Q3
3 quarters
DGAC.U icon
95
Disciplined Growth Acquisition Corp Units
DGAC.U
$5.02M 0.23%
+500,000
New +$5.01M
2026 Q2
0 quarters
BHAVU icon
96
BHAV Acquisition Corp Units
BHAVU
$5M 0.23%
495,000
– –
2026 Q1
1 quarter
DHR icon
97
Danaher
DHR
$158B
$4.94M 0.23%
25,932
-5,000
-16% -$908K
2025 Q4
2 quarters
BOLD icon
98
Boundless Bio
BOLD
$55.2M
$4.92M 0.23%
+1,968,216
New +$3.03M
2026 Q2
0 quarters
AVLN icon
99
Avalyn Pharma
AVLN
$1.05B
$4.82M 0.22%
+146,447
New +$4.23M
2026 Q2
0 quarters
SPRY icon
100
ARS Pharmaceuticals
SPRY
$391M
$4.81M 0.22%
600,999
-760,537
-56% -$6.54M
2025 Q3
3 quarters
2 3
4
5 6

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.